focus -WSS

focus

author：fashion 2025-09-29 17:02:36 - browse：553

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Stopping antidepressants leads to symptoms for 1 in 6 patients

focus

hotspot

WSS

Elevance PBM president out as customers face prescription chaos

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

Snowpack in the West is melting rapidly. Where will all that extra water go?

Stopping antidepressants leads to symptoms for 1 in 6 patients

Congress needs to close a vaccine

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

House GOP plan to stem drug shortages differs from Democrats’

Heart attack and stroke risk calculators need revising

HCA says smaller share of spending going to labor

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Doctors increasingly discourage vaping amid mounting health concerns

Dobbs anniversary: the lost opportunity of abortion as health care

Elevance PBM president out as customers face prescription chaos

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress needs to close a vaccine

entertainment

Illumina board agrees to spin off Grail, as divestment plans proceed

Stopping antidepressants leads to symptoms for 1 in 6 patients

Poland's lawmakers approve a divisive law on Russian influence

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Many immigrants are left out of maternal health programs

Teacher posts viral 'school supply rant' with advice for parents

focus

focus

hotspot

leisure time